Syndax Pharmaceuticals
Founded Year
2005Stage
IPO | IPOTotal Raised
$190.6MDate of IPO
3/3/2016Market Cap
1.92BStock Price
28.98Revenue
$0000About Syndax Pharmaceuticals
Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer. Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated in a Phase 1b/2 clinical trial for non-small cell lung cancer and melanoma and in a Phase 3 clinical trial for advanced HR+ breast cancer. The company was founded in 2005 and is based in Waltham, Massachusetts.
Missing: Syndax Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Syndax Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Syndax Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Syndax Pharmaceuticals is included in 3 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Syndax Pharmaceuticals Patents
Syndax Pharmaceuticals has filed 11 patents.
The 3 most popular patent topics include:
- Experimental cancer drugs
- Histone deacetylase inhibitors
- Monoclonal antibodies

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
9/2/2016 | 7/26/2022 | Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Indoles | Grant |
Application Date | 9/2/2016 |
---|---|
Grant Date | 7/26/2022 |
Title | |
Related Topics | Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Indoles |
Status | Grant |
Latest Syndax Pharmaceuticals News
Jan 4, 2023
01/04/2023 | 07:01am EST Message : *Required fields WALTHAM, Mass., Jan. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 10:30 a.m. PT/ 1:30 p.m. ET. A live webcast of the presentation can be accessed from the Investor section of the Company's website at www.syndax.com , where a replay of the event will also be available for a limited time. About Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib (SNDX-5613), a highly selective inhibitor of the Menin–MLL binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn . Syndax Contacts
Syndax Pharmaceuticals Frequently Asked Questions (FAQ)
When was Syndax Pharmaceuticals founded?
Syndax Pharmaceuticals was founded in 2005.
Where is Syndax Pharmaceuticals's headquarters?
Syndax Pharmaceuticals's headquarters is located at 35 Gatehouse Drive, Waltham.
What is Syndax Pharmaceuticals's latest funding round?
Syndax Pharmaceuticals's latest funding round is IPO.
How much did Syndax Pharmaceuticals raise?
Syndax Pharmaceuticals raised a total of $190.6M.
Who are the investors of Syndax Pharmaceuticals?
Investors of Syndax Pharmaceuticals include Forward Ventures, Domain Associates, MPM Capital, Tavistock Group, RMI Partners and 13 more.
Who are Syndax Pharmaceuticals's competitors?
Competitors of Syndax Pharmaceuticals include ISA Pharmaceuticals, Cornerstone Pharmaceuticals, Esperance Pharmaceuticals, OncoMed Pharmaceuticals, PNP Therapeutics, LIDDS, SpiroGen, Amplimmune Immunology, Aragon Pharmaceuticals, LigoCyte Pharmaceuticals and 13 more.
Compare Syndax Pharmaceuticals to Competitors
Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.
Psimei Pharmaceuticals is developing boron-based drugs for applications in Photon Activation Therapy (PAT). This involves the use of standard radiotherapy to activate boron-based compounds which selectively target solid tumours. This results in an amplification of the therapeutic effect of conventional radiotherapy. Pre-clinical data for Psimei's lead product, PP200PAT, has demonstrated 90% true cure rates at 6 months in tumour models compared with 30% for conventional radiotherapy alone. It also enabled much shorter treatment regimes - days as opposed to weeks. This drug is being prepared for clinical development.
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Retroscreen Virology has developed a business system with two principal units. The first is a Clinical Services business built around Human Viral Challenge Model and the second is a Translational Research (Pre-Clinical) business, built around in-house expertise on testing antivirals and virucidals in-vitro.
Activate Immunotherapy (formerly NovaRx) is a clinical-stage immuno-oncology company based in San Diego, California. Activate utilizes a novel approach for activating the body's immune system to recognize and destroy cancer cells. The company's most advanced immunotherapy, Lucanix, has been tested in late stage clinical trials as a treatment for non-small cell lung cancer (NSCLC), the largest cancer indication in the world. Lucanix has promising Phase 2 and Phase 3 data. In Lucanix's Phase 2 trial, the company demonstrated a significant improvement in survival for NSCLC patients. NovaRx completed a 532 patient Phase 3 study in early 2013. While the Phase 3 study missed the statistical endpoint for approval, survival benefits were shown if non United States clinical sites were excluded, particularly with patients who started Lucanix treatment within 12 weeks of chemotherapy and/or patients with prior chemotherapy and radiation therapy. Activate's proprietary platform technology is applicable to other solid tumors.
Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.